Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 12/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 11/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 8/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14424383 | 1.00 | ENPP3 (0.53) | ENPP3ENPP1ENPP2STSPOLB | |
| SCHEMBL10114618 | 0.99 | ENPP3 (0.51) | ENPP3ENPP1ENPP2STSPOLB | |
| SCHEMBL14424355 | 0.99 | ENPP3 (0.51) | ENPP3ENPP1ENPP2STSPOLB | |
| SCHEMBL13204264 | 0.89 | HRH3 (0.44) | ENPP3ENPP1ENPP2STSNPSR1 | |
| SCHEMBL10114664 | 0.89 | HRH3 (0.44) | ENPP3ENPP1ENPP2STSNPSR1 | |
| SCHEMBL13204426 | 0.89 | PTPN1 (0.56) | ENPP3ENPP1ENPP2STSLMNA | |
| SCHEMBL10114938 | 0.89 | PTPN1 (0.56) | ENPP3ENPP1ENPP2STSLMNA | |
| SCHEMBL10114933 | 0.88 | LMNA (0.48) | POLBLMNASMN1; SMN2NPSR1ABL1 | |
| SCHEMBL14424388 | 0.88 | LMNA (0.48) | POLBLMNASMN1; SMN2NPSR1ABL1 | |
| SCHEMBL14424357 | 0.86 | POLB (0.47) | POLBLMNASMN1; SMN2NPSR1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | ENPP3 3334/4885ENPP1 3255/4885ENPP2 546/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | ENPP3 3225/4885ENPP1 3059/4885ENPP2 459/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | ENPP3 3416/4885ENPP1 3327/4885ENPP2 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.